Mutual exclusivity analysis identifies oncogenic network modules

Genome Research

Volumn 22, Issue 2, 2012, Pages 398-406

  Ciriello, Giovanni ^a   Cerami, Ethan ^a,b   Sander, Chris ^a   Schultz, Nikolaus ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Tri Institutional Training Program in Computational Biology and Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RETINOBLASTOMA BINDING PROTEIN; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER GENETICS; CCNE1 GENE; CELL CYCLE REGULATION; CORRELATION ANALYSIS; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ALGORITHMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLIOBLASTOMA; HUMANS; INTERNET; MALE; MODELS, GENETIC; NEOPLASMS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; SOFTWARE;

EID: 84856535081     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.125567.111     Document Type: Article

References (51)

1. Barabási AL, Gulbahce N, Loscalzo J. 2011. Network medicine: A network-based approach to human disease. Nat Rev Genet 12: 56-68.
2. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, et al. 2007. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. Proc Natl Acad Sci 104: 20007-20012.
3. Boca SM, Kinzler KW, Velculescu VE, Vogelstein B, Parmigiani G. 2010. Patient-oriented gene set analysis for cancer mutation data. Genome Biol 11: R112. doi: 10.1186/gb-2010-11-11-r112.
4. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R, et al. 2009. A network model of a cooperative genetic landscape in brain tumors. JAMA 302: 261-275.
5. The Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
6. The Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
7. Carter H, Chen S, Isik L, Tyekucheva S, Velculescu VE, Kinzler KW, Vogelstein B, Karchin R. 2009. Cancer-specific high-throughput annotation of somatic mutations: Computational prediction of driver missense mutations. Cancer Res 69: 6660-6667.
8. Cerami E, Demir E, Schultz N, Taylor BS, Sander C. 2010. Automated network analysis identifies core pathways in glioblastoma. PLoS One 5: e8918. doi: 10.1371/journal.pone.0008918.
9. Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, Schultz N, Bader GD, Sander C. 2011. Pathway commons, a web resource for biological pathway data. Nucleic Acids Res 39: D685-D690.
10. Chen PL, Liu F, Cai S, Lin X, Li A, Chen Y, Gu B, Lee EYHP, Lee WH. 2005. Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insufficiency. Mol Cell Biol 25: 3535-3542. (Pubitemid 40559560)
11. Cowin PA, Anglesio M, Etemadmoghadam D, Bowtell DDL. 2010. Profiling the cancer genome. Annu Rev Genomics Hum Genet 11: 133-159.
12. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, et al. 2009. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15: 1417-1427.
13. Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Australian Ovarian Cancer Study Group, Gorringe KL, Smyth GK, Bowtell DDL. 2010. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE 5: e15498. doi: 10.1371/journal.pone.0015498.
14. Fukuda K. 2008. INOH pathway database: Curation, annotation, integration. InterOntology08 1: 47-50.
15. Getz G, Hofling H, Mesirov JP, Golub TR, Meyerson M, Tibshirani R, Lander ES. 2007. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science 317: 1500. doi: 10.1126/science.1138764.
16. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, et al. 2010. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS ONE 5. doi: 10.1371/journal.pone.0011408.
17. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158. (Pubitemid 46398669)
18. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
19. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
20. Hartwell LH, Hopfield JJ, Leibler S, Murray AW. 1999. From molecular to modular cell biology. Nature (Suppl) 402: C47-C52.
21. Hwang HC, Clurman BE. 2005. Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786. (Pubitemid 40638089)
22. Kaminker JS, Zhang Y, Watanabe C, Zhang Z. 2007. CanPredict: A computational tool for predicting cancer-associated missense mutations. Nucleic Acids Res 35: W595-W598.
23. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T, et al. 2008. KEGG for linking genomes to life and the environment. Nucleic Acids Res 36: D480-D484. (Pubitemid 351149770)
24. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, et al. 2009. Human Protein Reference Database-2009 update. Nucleic Acids Res 37: D767-D772.
25. Liben-Nowell D, Kleinberg J. 2003. The link prediction problem for social networks. In Proceedings of the Twelfth International Conference on Information and Knowledge Management, pp. 556-559. New York, NY.
26. Liu F, Lee WH. 2006. CtIP activates its own and cyclin D1 promoters via the E2F/Rb pathway during G1/S progression. Mol Cell Biol 26: 3124-3134.
27. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, Garapati P, Hemish J, Hermjakob H, Jassal B, et al. 2009. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 37: D619-D622.
28. Memorial Sloan-Kettering Cancer Center. 2007. Cancer cell map. http://cancer.cellmap.org/.
29. Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, Thomas PD. 2010. PANTHER version 7: Improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res 38: D204-D210.
30. Nakayama N, Nakayama K, Shamima Y, Ishikawa M, Katagiri A, Iida K, Miyazaki K. 2010. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116: 2621-2634.
31. Ng CC, Arakawa H, Fukuda S, Kondoh H, Nakamura Y. 2003. p53RFP, a p53-inducible RING-finger protein, regulates the stability of p21WAF1. Oncogene 22: 4449-4458. (Pubitemid 36897976)
32. Ohgaki H, Kleihues P. 2007. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170: 1445-1453. (Pubitemid 47339290)
33. Oti M, Snel B, Huynen MA, Brunner HG. 2006. Predicting disease genes using protein-protein interactions. J Med Genet 43: 691-698. (Pubitemid 44214908)
34. Pradines J, Rudolph-Owen L, Hunter J, Leroy P, Cary M, Coopersmith R, Dancik V, Eltsefon Y, Farutin V, Leroy C, et al. 2004. Detection of activity centers in cellular pathways using transcript profiling. J Biopharm Stat 14: 701-721. (Pubitemid 39296094)
35. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. 2002. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934. (Pubitemid 34976022)
36. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH. 2009. PID: The Pathway Interaction Database. Nucleic Acids Res 37: D674-D679.
37. Sherr CJ, McCormick F. 2002. The Rb and p53 pathways in cancer. Cancer Cell 2: 103-112. (Pubitemid 41039110)
38. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. 1998. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 58: 1130-1134. (Pubitemid 28183198)
39. Stecca B, i Altalba AR. 2009. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 28: 663-676.
40. Stratton MR, Campbell PJ, Futreal PA. 2009. The cancer genome. Nature 458: 719-724.
41. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. 2005. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci 102: 15545-15550. (Pubitemid 41528093)
42. Taylor BS, Barretina J, Socci ND, Decarolis P, Ladanyi M, Meyerson M, Singer S, Sander C. 2008. Functional copy-number alterations in cancer. PLoS ONE 3: e3179. doi: 10.1371/journal.pone.0003179.
43. Torkamani A, Schork NJ. 2009. Identification of rare cancer driver mutations by network reconstruction. Genome Res 19: 1570-1578.
44. Turner N, Tutt A, Ashworth A. 2004. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 4: 814-819.
45. Vandin F, Upfal E, Raphael BJ. 2010. Algorithms for detecting significantly mutated pathways in cancer. In Proceedings of the 14th Annual International Conference on Research in Computational Molecular Biology (RECOMB). Lisbon, Portugal.
46. Vaske CJ, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. 2010. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using paradigm. Bioinformatics 26: i237-i245.
47. Velculescu VE. 2008. Defining the blueprint of the cancer genome. Carcinogenesis 29: 1087-1091. (Pubitemid 351958685)
48. Wernicke S. 2006. Efficient detection of network motifs. IEEE/ACM Trans Comput Biol Bioinform 3: 347-359.
49. Westfall PH, Young S. 1993. Resampling-based multiple testing: Examples and methods for P-value adjustment. Wiley, New York.
50. Wu G, Feng X, Stein L. 2010. A human functional protein interaction network and its application to cancer data analysis. Genome Biol 11: R53. doi: 10.1186/gb-2010-11-5-r53.
51. Yu X, Chen J. 2004. DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 24: 9478-9486. (Pubitemid 39391684)